Q2 EPS Estimates for CVS Health Raised by Leerink Partnrs

CVS Health Co. (NYSE:CVS) – Analysts at Leerink Partnrs lifted their Q2 2025 earnings estimates for shares of CVS Health in a report released on Monday, November 18th. Leerink Partnrs analyst M. Cherny now forecasts that the pharmacy operator will post earnings per share of $1.71 for the quarter, up from their prior forecast of $1.64. The consensus estimate for CVS Health’s current full-year earnings is $5.43 per share. Leerink Partnrs also issued estimates for CVS Health’s Q3 2025 earnings at $1.81 EPS.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $1.08 by $0.01. The company had revenue of $95.43 billion for the quarter, compared to analyst estimates of $92.72 billion. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. CVS Health’s revenue for the quarter was up 6.3% on a year-over-year basis. During the same quarter last year, the business earned $2.21 EPS.

Other equities analysts also recently issued research reports about the stock. Truist Financial reissued a “buy” rating and issued a $67.00 target price (down previously from $76.00) on shares of CVS Health in a research note on Wednesday. UBS Group raised their target price on shares of CVS Health from $60.00 to $62.00 and gave the company a “neutral” rating in a research note on Thursday, November 7th. TD Cowen raised shares of CVS Health from a “hold” rating to a “buy” rating and raised their target price for the company from $59.00 to $85.00 in a research note on Friday, October 4th. StockNews.com downgraded shares of CVS Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Finally, Wells Fargo & Company raised shares of CVS Health from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $60.00 to $66.00 in a research note on Monday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average target price of $72.28.

CVS Health Stock Performance

Shares of CVS stock opened at $57.07 on Wednesday. The company’s fifty day simple moving average is $59.20 and its 200-day simple moving average is $58.60. CVS Health has a 52 week low of $52.71 and a 52 week high of $83.25. The company has a current ratio of 0.80, a quick ratio of 0.59 and a debt-to-equity ratio of 0.80. The company has a market cap of $71.81 billion, a PE ratio of 14.48, a P/E/G ratio of 0.94 and a beta of 0.55.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Monday, October 21st were paid a $0.665 dividend. The ex-dividend date was Monday, October 21st. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.66%. CVS Health’s dividend payout ratio (DPR) is presently 67.51%.

Institutional Investors Weigh In On CVS Health

Institutional investors have recently modified their holdings of the stock. Westside Investment Management Inc. raised its stake in CVS Health by 4.6% during the third quarter. Westside Investment Management Inc. now owns 64,517 shares of the pharmacy operator’s stock worth $4,041,000 after acquiring an additional 2,856 shares during the period. Soltis Investment Advisors LLC raised its stake in CVS Health by 1.3% during the third quarter. Soltis Investment Advisors LLC now owns 100,789 shares of the pharmacy operator’s stock worth $6,338,000 after acquiring an additional 1,342 shares during the period. TD Private Client Wealth LLC raised its stake in CVS Health by 28.7% during the third quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator’s stock worth $2,951,000 after acquiring an additional 10,465 shares during the period. Toronto Dominion Bank raised its stake in CVS Health by 124.6% during the third quarter. Toronto Dominion Bank now owns 1,508,071 shares of the pharmacy operator’s stock worth $94,828,000 after acquiring an additional 836,569 shares during the period. Finally, Coldstream Capital Management Inc. raised its stake in CVS Health by 27.8% during the third quarter. Coldstream Capital Management Inc. now owns 17,400 shares of the pharmacy operator’s stock worth $1,084,000 after acquiring an additional 3,788 shares during the period. Institutional investors and hedge funds own 80.66% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.